If the world needed any proof that money's still flowing in biotech, Portola Pharmaceuticals Inc. provided it by raising about $99.6 million in a public offering, and 2015's numbers so far regarding follow-on financings show a sharp trend upward, thanks partly to the parade of IPOs last year.